>The further it goes down the harder you have to consider the alternative that all isn't as it seems to be.<
Write the company and ask them what they've disclosed to major shareholders that they have not disclosed to us.
The real issue here for long-term shareholders isn't where the price is now, it's where it is when Javelin has to raise more cash, which should be late next year.
Agitate a little...after all, you do own part of this company, and the people below work for you.
Would suggest copying senior management on any messages to Ricky.
**************************************************************
Daniel B. Carr, MD
Chief Executive Officer & Chief Medical Officer
dcarr@javelinpharmaceuticals.com
Fred H. Mermelstein, Ph.D.
President
fmermelstein@javelinpharmaceuticals.com
Stephen J. Tulipano, CPA, MBA
Chief Financial Officer
stulipano@javelinpharmaceuticals.com
Michael T. Sheckler, MBA
VP, Business Development
msheckler@javelinpharmaceuticals.com
June C. Gregg
Corporate Communications
jgregg@javelinpharmaceuticals.com
Frederick "Rick" E. Pierce, II
VP, Investor Relations
rpierce@javelinpharmaceuticals.com